Targeted Cancer Therapies: Their Use, Effectiveness And Cost Effectiveness In Real World Clinical Practice
Funder
National Health and Medical Research Council
Funding Amount
$121,682.00
Summary
Cancer treatments come at a high price tag and are also released to the market earlier than ever before. The high costs can be a barrier to public funding and patient access and their early release means their risks and benefits are not fully understood, especially in the long-term. This project aims to examine the newer biological therapies - their use, costs and benefits in real-world clinical practice.
Could Pharmacological Restoration Of Mecp2 Levels Be Of Therapeutic Value In Rett Syndrome?
Funder
National Health and Medical Research Council
Summary
Rett syndrome is one of the commonest single gene cause of developmental disability in girls; 1:8500 Australian females are affected by the age of 12. There is currently no cure. Rett syndrome most commonly results from a fault in one copy of the Mecp2 gene on the X chromosome. The proposed research aims to identify medicines, already known to be safe in children and adults, which specifically improve the functioning of the Mecp2 gene. This should rapidly lead to targeted clinical treatments for ....Rett syndrome is one of the commonest single gene cause of developmental disability in girls; 1:8500 Australian females are affected by the age of 12. There is currently no cure. Rett syndrome most commonly results from a fault in one copy of the Mecp2 gene on the X chromosome. The proposed research aims to identify medicines, already known to be safe in children and adults, which specifically improve the functioning of the Mecp2 gene. This should rapidly lead to targeted clinical treatments for this condition.Read moreRead less
Genetic And Epigenetic Mechanisms Determining Responses To Therapies In Non-small Cell Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$22,677.00
Summary
Lung cancer results in more cancer related deaths than any other cancer. The aim of this study is to identify prognostic and predictive markers for patients with non-small cell lung cancer (NSCLC) treated with chemotherapy, palliative radiotherapy and also novel targeted agents. This will help to better utilise these treatments and hopefully improve outcomes in patients with NSCLC.